Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 26, 2018 16:30 ET | Source: AIT Therapeutics, Inc.

AIT Therapeutics Receives Patent Allowance for Delivery of Inhaled Nitric Oxide at Concentrations of at Least 160ppm for Treatment of Bronchiolitis in Infants

Bronchiolitis is primarily caused by respiratory syncytial virus (RSV) NEW YORK, April 26, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTC:AITB), a clinical-stage medical device and...
April 16, 2018 08:30 ET | Source: AIT Therapeutics, Inc.

AIT Therapeutics Names Stephen J. DiPalma as Chief Financial Officer

Industry veteran brings over 30 years of experience to AIT NEW YORK, April 16, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTC:AITB), a clinical-stage medical device and biopharmaceutical...
March 29, 2018 08:30 ET | Source: AIT Therapeutics, Inc.

AIT Granted New Patent for Its Nitric Oxide (NO) Generator and Delivery System

Patent covers technology for a disposable that filters nitrogen dioxide (NO2) gas and programs the system for use NEW YORK, March 29, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTC:AITB), a...
March 19, 2018 16:01 ET | Source: AIT Therapeutics, Inc.

AIT Therapeutics Reports Year End 2017 Financial Results

Expects first regulatory filing for the NO Generator and Delivery System in persistent pulmonary hypertension of the newborn (PPHN) by end of 2018 Closed global, exclusive license for revolutionary...
March 13, 2018 08:00 ET | Source: AIT Therapeutics, Inc.

AIT Therapeutics Announces Year End 2017 Financial Results Conference Call and Webcast

Call Scheduled for Monday, March 19, 2018 at 4:30pm Eastern Time. NEW YORK, March 13, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused...
March 07, 2018 16:05 ET | Source: AIT Therapeutics, Inc.

AIT Therapeutics to Present at Two Investor Conferences

REHOVOT, Israel and NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the...
February 20, 2018 16:30 ET | Source: AIT Therapeutics, Inc.

AIT Therapeutics Appoints Two Senior Executives in Research and Clinical Operations

Mark Rimkus Appointed VP of Clinical Affairs and Dr. Abdi Ghaffari Appointed VP of Research Appointments Add Decades of Nitric Oxide Experience to Team NEW YORK, Feb. 20, 2018 (GLOBE NEWSWIRE) --...
February 16, 2018 11:03 ET | Source: AIT Therapeutics, Inc.

AIT Therapeutics Announces $9.82 Million Private Placement

NEW YORK, Feb. 16, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients...
January 31, 2018 16:01 ET | Source: AIT Therapeutics, Inc.

AIT Therapeutics Announces Completion of the Agreement to License the Revolutionary Nitric Oxide (NO) Generator and Delivery System

First Regulatory Filing for the eNOGenerator System Expected By End of 2018 NEW YORK, Jan. 31, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company...
January 22, 2018 08:00 ET | Source: AIT Therapeutics, Inc.

AIT Therapeutics Announces Further Data From Its NO-NTM Abscessus Phase 2 Clinical Trial in Nontuberculous Mycobacteria (NTM) Patients

Mycobacterium Abscessus Load Reduced by 65% 6-Minute Walk Improvement Maintained at Day 81 NEW YORK, Jan. 22, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (OTC:AITB), a clinical-stage...